Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies—A single institution experience and a review of literature
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/1078155218788707
Abstract: Background Ibrutinib, a Bruton’s tyrosine kinase inhibitor has reformed the treatment of various B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom’s macroglobulinemia. Although generally well tolerated, here we describe our institutional experience… read more here.
Keywords: cell malignancies; unique adverse; treatment; case series ... See more keywords